{"id":"bivalent-moderna","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL4576598","moleculeType":"Unknown","molecularWeight":"887.04"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses lipid nanoparticle-formulated mRNA to instruct cells to produce spike proteins from both the original Wuhan strain and the Omicron variant, triggering both humoral and cellular immune responses. This bivalent approach aims to provide broader protection against circulating SARS-CoV-2 variants compared to monovalent vaccines.","oneSentence":"Bivalent Moderna is a bivalent mRNA vaccine that encodes antigens targeting two variants of SARS-CoV-2 to elicit adaptive immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:25.106Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults and children (booster vaccination)"}]},"trialDetails":[{"nctId":"NCT05658523","phase":"PHASE3","title":"COVID-19 Booster Study in Healthy Adults in Australia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-02-28","conditions":"COVID-19","enrollment":496},{"nctId":"NCT05543993","phase":"","title":"COVID Booster in Pregnancy and Lactation","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-09-29","conditions":"COVID-19","enrollment":150},{"nctId":"NCT05584202","phase":"PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants","status":"TERMINATED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-30","conditions":"SARS-CoV-2","enrollment":68},{"nctId":"NCT05168813","phase":"PHASE2, PHASE3","title":"Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern","status":"COMPLETED","sponsor":"COVID-19 Prevention Network","startDate":"2021-12-01","conditions":"SARS-CoV-2 Infection, HIV Infections, COVID-19","enrollment":14237},{"nctId":"NCT05556720","phase":"PHASE3","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2022-12-01","conditions":"HIV, Organ Transplantation, Lymphoma, Non-Hodgkin","enrollment":960},{"nctId":"NCT05000216","phase":"PHASE2","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-13","conditions":"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris","enrollment":258},{"nctId":"NCT06113692","phase":"","title":"A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-31","conditions":"Myocarditis, Pericarditis","enrollment":1169},{"nctId":"NCT05518487","phase":"PHASE2","title":"COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-02-20","conditions":"COVID-19, Kidney Transplant","enrollment":15},{"nctId":"NCT05933304","phase":"","title":"A Study of the Effectiveness of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-12-18","conditions":"SARS-CoV-2, COVID-19","enrollment":927004},{"nctId":"NCT06333704","phase":"","title":"Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-03-10","conditions":"SARS-CoV-2","enrollment":4206},{"nctId":"NCT06130345","phase":"","title":"Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2","enrollment":15196685},{"nctId":"NCT06441955","phase":"PHASE4","title":"Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.","status":"RECRUITING","sponsor":"Well- Konnect Healthcare Services and Research Firm","startDate":"2024-03-01","conditions":"COVID-19, Long Haul","enrollment":100},{"nctId":"NCT05765578","phase":"","title":"An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-08","conditions":"COVID-19","enrollment":1713},{"nctId":"NCT05543356","phase":"PHASE3","title":"COVID-19 Fourth Dose Study in Australia","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05308602","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years","status":"WITHDRAWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-04-01","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":""},{"nctId":"NCT04805125","phase":"PHASE3","title":"Immunocompromised Swiss Cohorts Based Trial Platform","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-19","conditions":"Immunocompromised Patients","enrollment":610},{"nctId":"NCT04977479","phase":"PHASE2","title":"The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-08","conditions":"Systemic Allergic Reaction","enrollment":20},{"nctId":"NCT05236491","phase":"PHASE2, PHASE3","title":"COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases","status":"UNKNOWN","sponsor":"Paul R Fortin","startDate":"2022-03-09","conditions":"Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus","enrollment":287}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":62,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["mRNA-1273.214 +B.1.1.529 OMI","mRNA-1273.214"],"phase":"phase_3","status":"active","brandName":"Bivalent Moderna","genericName":"Bivalent Moderna","companyName":"Murdoch Childrens Research Institute","companyId":"murdoch-childrens-research-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"Bivalent Moderna is a bivalent mRNA vaccine that encodes antigens targeting two variants of SARS-CoV-2 to elicit adaptive immune responses. Used for COVID-19 prevention in adults and children (booster vaccination).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}